Wendy Kohrt
Concepts (663)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 45 | 2024 | 489 | 6.810 |
Why?
| | Exercise | 68 | 2024 | 2057 | 5.100 |
Why?
| | Body Composition | 54 | 2024 | 684 | 4.520 |
Why?
| | Bone and Bones | 16 | 2021 | 317 | 3.400 |
Why?
| | Postmenopause | 31 | 2020 | 366 | 3.270 |
Why?
| | Parathyroid Hormone | 9 | 2021 | 108 | 3.260 |
Why?
| | Menopause | 13 | 2022 | 320 | 2.940 |
Why?
| | Estrogens | 21 | 2024 | 367 | 2.920 |
Why?
| | Bone Resorption | 7 | 2022 | 86 | 2.630 |
Why?
| | Estradiol | 18 | 2024 | 521 | 2.630 |
Why?
| | Calcium | 7 | 2021 | 1199 | 2.250 |
Why?
| | Premenopause | 11 | 2020 | 131 | 2.210 |
Why?
| | Estrogen Replacement Therapy | 16 | 2019 | 146 | 2.170 |
Why?
| | Exercise Therapy | 19 | 2025 | 443 | 2.140 |
Why?
| | Gonadotropin-Releasing Hormone | 9 | 2024 | 212 | 2.110 |
Why?
| | Energy Metabolism | 16 | 2024 | 922 | 1.950 |
Why?
| | Parkinson Disease | 16 | 2025 | 493 | 1.830 |
Why?
| | Estrogens, Conjugated (USP) | 9 | 2017 | 49 | 1.820 |
Why?
| | Endothelium, Vascular | 11 | 2025 | 927 | 1.800 |
Why?
| | Collagen Type I | 13 | 2021 | 136 | 1.800 |
Why?
| | Walking | 11 | 2021 | 529 | 1.790 |
Why?
| | Resistance Training | 9 | 2024 | 164 | 1.730 |
Why?
| | Calcium, Dietary | 7 | 2017 | 57 | 1.620 |
Why?
| | Middle Aged | 128 | 2025 | 33479 | 1.450 |
Why?
| | Adipose Tissue | 25 | 2022 | 635 | 1.440 |
Why?
| | Osteoporosis, Postmenopausal | 9 | 2019 | 42 | 1.420 |
Why?
| | Dehydroepiandrosterone | 5 | 2018 | 51 | 1.420 |
Why?
| | Lumbar Vertebrae | 11 | 2021 | 246 | 1.400 |
Why?
| | Femur Neck | 8 | 2020 | 61 | 1.390 |
Why?
| | Aging | 29 | 2025 | 1864 | 1.350 |
Why?
| | Aged | 114 | 2025 | 23961 | 1.340 |
Why?
| | Female | 181 | 2025 | 73304 | 1.300 |
Why?
| | Insulin | 26 | 2022 | 2409 | 1.280 |
Why?
| | Ovary | 4 | 2024 | 221 | 1.270 |
Why?
| | Peptides | 12 | 2021 | 985 | 1.220 |
Why?
| | Homeostasis | 7 | 2019 | 621 | 1.200 |
Why?
| | Bicycling | 9 | 2014 | 114 | 1.200 |
Why?
| | Humans | 235 | 2025 | 137585 | 1.180 |
Why?
| | Hormone Replacement Therapy | 9 | 2018 | 100 | 1.180 |
Why?
| | Lipolysis | 6 | 2014 | 46 | 1.160 |
Why?
| | Glucose | 13 | 2024 | 1020 | 1.150 |
Why?
| | Cardiovascular Diseases | 14 | 2024 | 2111 | 1.130 |
Why?
| | Oxygen Consumption | 32 | 2025 | 696 | 1.080 |
Why?
| | Obesity | 21 | 2024 | 2992 | 1.040 |
Why?
| | Absorptiometry, Photon | 19 | 2024 | 259 | 1.040 |
Why?
| | Muscle, Skeletal | 17 | 2020 | 1724 | 1.020 |
Why?
| | Sleep Deprivation | 5 | 2022 | 174 | 0.990 |
Why?
| | Arthroplasty, Replacement, Knee | 9 | 2017 | 363 | 0.990 |
Why?
| | Adipocytes | 6 | 2025 | 222 | 0.950 |
Why?
| | Adiposity | 5 | 2018 | 518 | 0.950 |
Why?
| | Vasodilation | 9 | 2025 | 499 | 0.940 |
Why?
| | Vascular Stiffness | 6 | 2024 | 494 | 0.940 |
Why?
| | Sleep | 7 | 2022 | 755 | 0.940 |
Why?
| | Physical Endurance | 19 | 2015 | 275 | 0.920 |
Why?
| | Motor Activity | 11 | 2015 | 718 | 0.890 |
Why?
| | Insulin Resistance | 12 | 2025 | 1208 | 0.890 |
Why?
| | Follicle Stimulating Hormone | 6 | 2024 | 244 | 0.880 |
Why?
| | Frail Elderly | 6 | 2013 | 131 | 0.850 |
Why?
| | Weight Loss | 11 | 2024 | 787 | 0.850 |
Why?
| | Muscle Strength | 9 | 2024 | 317 | 0.850 |
Why?
| | Male | 132 | 2025 | 67762 | 0.850 |
Why?
| | Quadriceps Muscle | 5 | 2017 | 133 | 0.840 |
Why?
| | Adult | 89 | 2025 | 37929 | 0.840 |
Why?
| | Testosterone | 8 | 2025 | 409 | 0.820 |
Why?
| | Dehydroepiandrosterone Sulfate | 4 | 2013 | 46 | 0.800 |
Why?
| | Sweating | 2 | 2019 | 40 | 0.790 |
Why?
| | Glycerol | 8 | 2013 | 94 | 0.760 |
Why?
| | Hypothalamo-Hypophyseal System | 3 | 2018 | 197 | 0.750 |
Why?
| | Pituitary-Adrenal System | 2 | 2018 | 162 | 0.740 |
Why?
| | Double-Blind Method | 13 | 2018 | 1993 | 0.740 |
Why?
| | Leptin | 8 | 2025 | 236 | 0.740 |
Why?
| | Brachial Artery | 8 | 2025 | 205 | 0.710 |
Why?
| | Electric Stimulation Therapy | 2 | 2012 | 81 | 0.700 |
Why?
| | Bone Remodeling | 6 | 2022 | 75 | 0.690 |
Why?
| | Raloxifene Hydrochloride | 3 | 2017 | 15 | 0.690 |
Why?
| | Weight-Bearing | 7 | 2017 | 173 | 0.690 |
Why?
| | Trigger Points | 2 | 2018 | 13 | 0.690 |
Why?
| | Subcutaneous Fat | 3 | 2014 | 81 | 0.680 |
Why?
| | Exercise Test | 18 | 2024 | 625 | 0.640 |
Why?
| | Sex Factors | 10 | 2024 | 2071 | 0.640 |
Why?
| | Osteoarthritis, Knee | 6 | 2018 | 254 | 0.640 |
Why?
| | Skin | 4 | 2019 | 752 | 0.630 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 2018 | 68 | 0.620 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2021 | 350 | 0.610 |
Why?
| | Activities of Daily Living | 7 | 2020 | 413 | 0.600 |
Why?
| | Lactic Acid | 7 | 2018 | 305 | 0.590 |
Why?
| | Tension-Type Headache | 1 | 2018 | 8 | 0.590 |
Why?
| | Headache Disorders | 1 | 2018 | 18 | 0.590 |
Why?
| | Osteoporosis | 10 | 2024 | 243 | 0.580 |
Why?
| | Physical Fitness | 9 | 2014 | 209 | 0.580 |
Why?
| | Adaptation, Physiological | 4 | 2012 | 553 | 0.580 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2024 | 1477 | 0.570 |
Why?
| | Heart Rate | 20 | 2025 | 822 | 0.570 |
Why?
| | Massage | 1 | 2018 | 43 | 0.570 |
Why?
| | Biomarkers | 16 | 2025 | 4149 | 0.550 |
Why?
| | Weight Gain | 3 | 2011 | 519 | 0.550 |
Why?
| | Regional Blood Flow | 3 | 2018 | 474 | 0.540 |
Why?
| | Immunoglobulin G | 3 | 2021 | 893 | 0.530 |
Why?
| | Health | 3 | 2017 | 84 | 0.530 |
Why?
| | Abdomen | 9 | 2005 | 125 | 0.520 |
Why?
| | Leuprolide | 2 | 2017 | 20 | 0.510 |
Why?
| | Blood Glucose | 22 | 2013 | 2186 | 0.510 |
Why?
| | Hot Temperature | 1 | 2019 | 391 | 0.510 |
Why?
| | Ibuprofen | 2 | 2021 | 84 | 0.490 |
Why?
| | Aged, 80 and over | 24 | 2019 | 7635 | 0.490 |
Why?
| | Osteogenesis | 5 | 2020 | 188 | 0.490 |
Why?
| | Exercise Tolerance | 4 | 2025 | 279 | 0.490 |
Why?
| | Dietary Supplements | 2 | 2017 | 561 | 0.480 |
Why?
| | Glucose Clamp Technique | 13 | 2014 | 195 | 0.480 |
Why?
| | Medroxyprogesterone Acetate | 5 | 2003 | 36 | 0.470 |
Why?
| | Glucose Tolerance Test | 12 | 2013 | 366 | 0.470 |
Why?
| | Antibodies | 1 | 2017 | 410 | 0.470 |
Why?
| | Hypogonadism | 4 | 2024 | 92 | 0.470 |
Why?
| | Selective Estrogen Receptor Modulators | 2 | 2017 | 29 | 0.460 |
Why?
| | Severity of Illness Index | 11 | 2018 | 2828 | 0.460 |
Why?
| | Medroxyprogesterone | 2 | 2007 | 11 | 0.450 |
Why?
| | Health Status | 4 | 2020 | 792 | 0.440 |
Why?
| | Gonadal Steroid Hormones | 4 | 2021 | 140 | 0.440 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2025 | 36 | 0.440 |
Why?
| | Perimenopause | 4 | 2022 | 63 | 0.430 |
Why?
| | Young Adult | 20 | 2024 | 13209 | 0.430 |
Why?
| | Thigh | 3 | 2010 | 48 | 0.430 |
Why?
| | Body Weight | 14 | 2024 | 985 | 0.420 |
Why?
| | Running | 9 | 2015 | 230 | 0.410 |
Why?
| | Saliva | 2 | 2005 | 242 | 0.410 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 164 | 0.400 |
Why?
| | Femur | 6 | 2018 | 254 | 0.400 |
Why?
| | Deuterium | 6 | 2019 | 99 | 0.400 |
Why?
| | Cognition Disorders | 2 | 2015 | 496 | 0.390 |
Why?
| | Sweat | 4 | 2019 | 47 | 0.380 |
Why?
| | Carotid Arteries | 6 | 2024 | 206 | 0.380 |
Why?
| | Quality of Life | 8 | 2022 | 2892 | 0.370 |
Why?
| | Treatment Outcome | 18 | 2022 | 10811 | 0.370 |
Why?
| | Cognition | 3 | 2013 | 1153 | 0.360 |
Why?
| | Hydrocortisone | 3 | 2018 | 322 | 0.360 |
Why?
| | Heart-Assist Devices | 3 | 2023 | 552 | 0.360 |
Why?
| | Hormone Antagonists | 1 | 2011 | 34 | 0.360 |
Why?
| | Baroreflex | 2 | 2022 | 57 | 0.360 |
Why?
| | Adipose Tissue, Brown | 2 | 2024 | 53 | 0.360 |
Why?
| | Analysis of Variance | 11 | 2018 | 1316 | 0.350 |
Why?
| | Physical Education and Training | 14 | 1996 | 76 | 0.350 |
Why?
| | Procollagen | 3 | 2020 | 23 | 0.350 |
Why?
| | Osteocalcin | 5 | 2022 | 37 | 0.350 |
Why?
| | Hip | 6 | 2012 | 56 | 0.340 |
Why?
| | Body Mass Index | 10 | 2019 | 2389 | 0.340 |
Why?
| | HIV Infections | 8 | 2020 | 2836 | 0.340 |
Why?
| | Ovariectomy | 5 | 2025 | 152 | 0.330 |
Why?
| | Sympathetic Nervous System | 1 | 2011 | 182 | 0.330 |
Why?
| | Disability Evaluation | 5 | 2013 | 290 | 0.330 |
Why?
| | Lipids | 6 | 2013 | 672 | 0.330 |
Why?
| | Glucose Intolerance | 5 | 2001 | 146 | 0.330 |
Why?
| | Women's Health | 4 | 2024 | 372 | 0.320 |
Why?
| | Sex Characteristics | 10 | 2024 | 762 | 0.320 |
Why?
| | Gravitation | 1 | 2009 | 18 | 0.320 |
Why?
| | Vasodilator Agents | 1 | 2012 | 331 | 0.320 |
Why?
| | Bone Density Conservation Agents | 2 | 2024 | 80 | 0.320 |
Why?
| | Acetaminophen | 1 | 2012 | 268 | 0.320 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 91 | 0.320 |
Why?
| | Menstrual Cycle | 2 | 2013 | 133 | 0.310 |
Why?
| | Osteoarthritis | 2 | 2015 | 185 | 0.310 |
Why?
| | Alkaline Phosphatase | 3 | 2021 | 148 | 0.310 |
Why?
| | Heart Failure | 4 | 2024 | 2236 | 0.300 |
Why?
| | Progesterone Congeners | 3 | 2003 | 16 | 0.290 |
Why?
| | Dyslipidemias | 1 | 2010 | 176 | 0.290 |
Why?
| | Range of Motion, Articular | 7 | 2017 | 393 | 0.290 |
Why?
| | Physical Exertion | 6 | 2001 | 215 | 0.290 |
Why?
| | Cross-Sectional Studies | 14 | 2022 | 5472 | 0.290 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1242 | 0.290 |
Why?
| | Adolescent | 15 | 2024 | 21513 | 0.290 |
Why?
| | Hematopoietic Stem Cells | 4 | 2025 | 406 | 0.280 |
Why?
| | Urine | 3 | 2004 | 59 | 0.280 |
Why?
| | Pain Measurement | 6 | 2018 | 521 | 0.280 |
Why?
| | Prospective Studies | 16 | 2019 | 7604 | 0.280 |
Why?
| | High-Intensity Interval Training | 2 | 2018 | 25 | 0.280 |
Why?
| | Pain Threshold | 3 | 2018 | 74 | 0.270 |
Why?
| | Circadian Rhythm | 4 | 2020 | 468 | 0.270 |
Why?
| | Sports | 5 | 2020 | 231 | 0.270 |
Why?
| | Fractures, Bone | 4 | 2016 | 380 | 0.260 |
Why?
| | Body Water | 2 | 2004 | 21 | 0.260 |
Why?
| | Area Under Curve | 6 | 2013 | 314 | 0.260 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2019 | 3715 | 0.260 |
Why?
| | Peptide Fragments | 3 | 2020 | 706 | 0.260 |
Why?
| | Triglycerides | 4 | 2011 | 524 | 0.260 |
Why?
| | Oxidative Stress | 5 | 2024 | 1317 | 0.250 |
Why?
| | Postural Balance | 6 | 2015 | 215 | 0.250 |
Why?
| | Microdialysis | 6 | 2012 | 52 | 0.240 |
Why?
| | Risk Factors | 12 | 2019 | 10388 | 0.240 |
Why?
| | Radioisotope Dilution Technique | 2 | 2004 | 14 | 0.240 |
Why?
| | Blood Coagulation | 1 | 2007 | 255 | 0.230 |
Why?
| | Cardiac Output | 5 | 2023 | 165 | 0.230 |
Why?
| | Heart Ventricles | 2 | 2020 | 788 | 0.230 |
Why?
| | Water | 2 | 2019 | 460 | 0.230 |
Why?
| | Cholesterol | 4 | 2011 | 410 | 0.230 |
Why?
| | Bone Marrow Cells | 3 | 2021 | 316 | 0.230 |
Why?
| | Basal Metabolism | 1 | 2005 | 61 | 0.230 |
Why?
| | Alendronate | 1 | 2024 | 15 | 0.230 |
Why?
| | Time Factors | 14 | 2019 | 6828 | 0.220 |
Why?
| | Diet | 8 | 2019 | 1278 | 0.220 |
Why?
| | Body Constitution | 2 | 2001 | 55 | 0.220 |
Why?
| | Serum | 1 | 2004 | 59 | 0.220 |
Why?
| | Recovery of Function | 6 | 2017 | 653 | 0.220 |
Why?
| | Cholesterol, HDL | 5 | 2011 | 203 | 0.220 |
Why?
| | Physical Conditioning, Animal | 5 | 2025 | 257 | 0.220 |
Why?
| | Regression Analysis | 6 | 2011 | 1024 | 0.210 |
Why?
| | HIV-1 | 4 | 2013 | 864 | 0.210 |
Why?
| | Placebos | 4 | 2011 | 199 | 0.210 |
Why?
| | Endothelin-1 | 1 | 2025 | 182 | 0.200 |
Why?
| | Blood Pressure | 10 | 2022 | 1786 | 0.200 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2024 | 135 | 0.200 |
Why?
| | Caloric Restriction | 1 | 2024 | 124 | 0.200 |
Why?
| | Sports Medicine | 1 | 2004 | 112 | 0.200 |
Why?
| | Adipose Tissue, White | 2 | 2024 | 41 | 0.200 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 55 | 0.200 |
Why?
| | Rats, Wistar | 1 | 2024 | 455 | 0.200 |
Why?
| | Diet, Reducing | 2 | 2001 | 89 | 0.190 |
Why?
| | Arginine | 4 | 2017 | 271 | 0.190 |
Why?
| | Cold Temperature | 2 | 2024 | 179 | 0.190 |
Why?
| | Thermogenesis | 2 | 2024 | 44 | 0.190 |
Why?
| | Intermittent Claudication | 2 | 2015 | 118 | 0.190 |
Why?
| | Circadian Clocks | 2 | 2019 | 50 | 0.190 |
Why?
| | Torque | 2 | 2012 | 84 | 0.180 |
Why?
| | Knee Joint | 6 | 2017 | 409 | 0.180 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2013 | 319 | 0.180 |
Why?
| | Weight Reduction Programs | 2 | 2014 | 117 | 0.180 |
Why?
| | Oxygen Isotopes | 2 | 2019 | 25 | 0.180 |
Why?
| | Ventricular Function, Right | 2 | 2020 | 285 | 0.180 |
Why?
| | Vitamin D | 3 | 2020 | 397 | 0.180 |
Why?
| | Ultrasonography | 7 | 2018 | 759 | 0.180 |
Why?
| | Intestinal Absorption | 1 | 2001 | 102 | 0.180 |
Why?
| | Proteins | 5 | 1998 | 1009 | 0.180 |
Why?
| | Pressoreceptors | 1 | 2021 | 19 | 0.170 |
Why?
| | Superficial Back Muscles | 2 | 2018 | 14 | 0.170 |
Why?
| | Polysaccharides | 2 | 2021 | 79 | 0.170 |
Why?
| | Glycosylation | 2 | 2021 | 151 | 0.170 |
Why?
| | Muscle Proteins | 3 | 2019 | 231 | 0.170 |
Why?
| | Dexamethasone | 2 | 2018 | 368 | 0.170 |
Why?
| | Postprandial Period | 1 | 2001 | 107 | 0.170 |
Why?
| | Animals | 23 | 2025 | 36940 | 0.170 |
Why?
| | Cross-Over Studies | 3 | 2014 | 564 | 0.170 |
Why?
| | Pulmonary Gas Exchange | 5 | 2017 | 121 | 0.170 |
Why?
| | Lactates | 8 | 2012 | 85 | 0.170 |
Why?
| | Hip Joint | 3 | 2019 | 171 | 0.170 |
Why?
| | Interleukin-6 | 2 | 2022 | 778 | 0.170 |
Why?
| | Luteal Phase | 2 | 2014 | 45 | 0.170 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2023 | 382 | 0.160 |
Why?
| | Carbohydrate Metabolism | 3 | 1998 | 59 | 0.160 |
Why?
| | Age Factors | 7 | 2025 | 3295 | 0.160 |
Why?
| | Pilot Projects | 6 | 2020 | 1710 | 0.160 |
Why?
| | Oxidation-Reduction | 5 | 2020 | 1060 | 0.160 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 25 | 0.160 |
Why?
| | Research Design | 4 | 2024 | 1139 | 0.160 |
Why?
| | Reference Values | 6 | 2013 | 816 | 0.160 |
Why?
| | Surveys and Questionnaires | 8 | 2019 | 5778 | 0.160 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 226 | 0.160 |
Why?
| | Coronary Disease | 2 | 2001 | 385 | 0.150 |
Why?
| | Myocardial Contraction | 1 | 2020 | 341 | 0.150 |
Why?
| | Patient Compliance | 4 | 2015 | 581 | 0.150 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2019 | 50 | 0.150 |
Why?
| | Health Behavior | 1 | 2004 | 762 | 0.150 |
Why?
| | Geographic Atrophy | 1 | 2019 | 79 | 0.150 |
Why?
| | Calcium Channels, L-Type | 1 | 2019 | 118 | 0.150 |
Why?
| | Cholesterol, LDL | 4 | 2011 | 365 | 0.150 |
Why?
| | Compliance | 2 | 2018 | 49 | 0.150 |
Why?
| | Homocysteine | 1 | 2019 | 156 | 0.150 |
Why?
| | Extracellular Fluid | 1 | 2018 | 31 | 0.150 |
Why?
| | Acidosis | 1 | 2019 | 101 | 0.150 |
Why?
| | Cortisone | 1 | 2018 | 12 | 0.150 |
Why?
| | Case-Control Studies | 7 | 2019 | 3556 | 0.150 |
Why?
| | Proof of Concept Study | 1 | 2018 | 78 | 0.150 |
Why?
| | Swimming | 2 | 1989 | 51 | 0.140 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2019 | 218 | 0.140 |
Why?
| | Ions | 1 | 2018 | 70 | 0.140 |
Why?
| | Cancellous Bone | 1 | 2017 | 23 | 0.140 |
Why?
| | Macular Degeneration | 1 | 2019 | 164 | 0.140 |
Why?
| | Osteoarthritis, Hip | 1 | 2018 | 45 | 0.140 |
Why?
| | Obesity, Abdominal | 2 | 2017 | 48 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 204 | 0.140 |
Why?
| | Cardiovascular Physiological Phenomena | 3 | 2015 | 42 | 0.140 |
Why?
| | omega-N-Methylarginine | 1 | 1997 | 27 | 0.140 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2018 | 143 | 0.140 |
Why?
| | Physical Therapy Modalities | 2 | 2012 | 308 | 0.140 |
Why?
| | Rest | 2 | 1997 | 121 | 0.140 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 238 | 0.130 |
Why?
| | Integrin beta1 | 1 | 2017 | 25 | 0.130 |
Why?
| | Growth Hormone | 1 | 1997 | 101 | 0.130 |
Why?
| | Isotope Labeling | 1 | 2017 | 81 | 0.130 |
Why?
| | Galactose | 1 | 2017 | 33 | 0.130 |
Why?
| | Forearm | 1 | 1997 | 119 | 0.130 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2018 | 125 | 0.130 |
Why?
| | Luteinizing Hormone | 2 | 2015 | 185 | 0.130 |
Why?
| | Hypokinesia | 1 | 2016 | 8 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2019 | 2531 | 0.130 |
Why?
| | Healthy Volunteers | 2 | 2017 | 199 | 0.130 |
Why?
| | Pelvic Bones | 1 | 2018 | 129 | 0.130 |
Why?
| | Lipid Metabolism | 3 | 1998 | 518 | 0.130 |
Why?
| | Osteoporotic Fractures | 1 | 2017 | 60 | 0.130 |
Why?
| | Gait Disorders, Neurologic | 1 | 2017 | 46 | 0.130 |
Why?
| | Electromyography | 2 | 2016 | 400 | 0.130 |
Why?
| | Peripheral Arterial Disease | 2 | 2015 | 475 | 0.130 |
Why?
| | Hyperinsulinism | 3 | 2003 | 121 | 0.130 |
Why?
| | Vascular Diseases | 1 | 2019 | 243 | 0.130 |
Why?
| | Mice | 8 | 2025 | 17787 | 0.130 |
Why?
| | Food, Fortified | 1 | 2016 | 42 | 0.120 |
Why?
| | Pain | 1 | 2001 | 756 | 0.120 |
Why?
| | Administration, Cutaneous | 3 | 2015 | 129 | 0.120 |
Why?
| | Stroke Volume | 6 | 2023 | 612 | 0.120 |
Why?
| | Energy Intake | 5 | 2013 | 485 | 0.120 |
Why?
| | Adipocytes, White | 1 | 2015 | 19 | 0.120 |
Why?
| | Gonadotropins | 1 | 2015 | 40 | 0.120 |
Why?
| | Muscle Strength Dynamometer | 2 | 2012 | 23 | 0.120 |
Why?
| | Aging, Premature | 2 | 2013 | 13 | 0.120 |
Why?
| | Nitric Oxide | 2 | 2017 | 915 | 0.120 |
Why?
| | Predictive Value of Tests | 4 | 2015 | 2031 | 0.120 |
Why?
| | Precision Medicine | 1 | 2019 | 429 | 0.110 |
Why?
| | Injections, Intravenous | 2 | 2006 | 206 | 0.110 |
Why?
| | Wrist Joint | 1 | 1995 | 62 | 0.110 |
Why?
| | Muscles | 7 | 2013 | 326 | 0.110 |
Why?
| | Stem Cells | 2 | 2017 | 594 | 0.110 |
Why?
| | Metabolomics | 1 | 2020 | 678 | 0.110 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2012 | 179 | 0.110 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5757 | 0.110 |
Why?
| | Anti-HIV Agents | 4 | 2014 | 778 | 0.110 |
Why?
| | Clinical Trials as Topic | 4 | 2016 | 1050 | 0.110 |
Why?
| | Accidental Falls | 2 | 2017 | 196 | 0.110 |
Why?
| | Linear Models | 2 | 2008 | 849 | 0.110 |
Why?
| | Mass Spectrometry | 1 | 2017 | 739 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 2691 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2057 | 0.110 |
Why?
| | Etanercept | 1 | 2013 | 57 | 0.100 |
Why?
| | Neck Pain | 1 | 2013 | 26 | 0.100 |
Why?
| | Spine | 1 | 1995 | 173 | 0.100 |
Why?
| | Catecholamines | 1 | 1993 | 98 | 0.100 |
Why?
| | Radiography | 2 | 2012 | 822 | 0.100 |
Why?
| | Health Status Indicators | 2 | 2011 | 171 | 0.100 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2844 | 0.100 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 131 | 0.100 |
Why?
| | Community Health Services | 1 | 2015 | 227 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2015 | 233 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5131 | 0.100 |
Why?
| | Microfluidics | 1 | 2013 | 54 | 0.100 |
Why?
| | C-Reactive Protein | 2 | 2022 | 410 | 0.100 |
Why?
| | Acupressure | 1 | 2012 | 6 | 0.100 |
Why?
| | Life Style | 3 | 2008 | 490 | 0.100 |
Why?
| | Mathematical Concepts | 1 | 2013 | 31 | 0.100 |
Why?
| | Hunger | 1 | 2013 | 45 | 0.100 |
Why?
| | Sensitivity and Specificity | 3 | 2005 | 1946 | 0.100 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2013 | 59 | 0.100 |
Why?
| | Femoral Neck Fractures | 1 | 2012 | 21 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 346 | 0.100 |
Why?
| | Myofascial Pain Syndromes | 1 | 2012 | 12 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1066 | 0.100 |
Why?
| | Posture | 1 | 1993 | 185 | 0.100 |
Why?
| | Steroids | 1 | 2013 | 167 | 0.100 |
Why?
| | Carbon Isotopes | 2 | 2006 | 144 | 0.100 |
Why?
| | Neuropsychological Tests | 2 | 2015 | 1023 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2012 | 48 | 0.090 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 56 | 0.090 |
Why?
| | Hemodynamics | 4 | 2023 | 1113 | 0.090 |
Why?
| | Sarcopenia | 1 | 2013 | 83 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2012 | 73 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 252 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 129 | 0.090 |
Why?
| | Incidence | 3 | 2019 | 2804 | 0.090 |
Why?
| | Headache | 1 | 2012 | 147 | 0.090 |
Why?
| | Gait | 4 | 2015 | 296 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2012 | 125 | 0.090 |
Why?
| | Oxytocics | 1 | 2011 | 15 | 0.090 |
Why?
| | Meals | 1 | 2013 | 125 | 0.090 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 433 | 0.090 |
Why?
| | Fatty Acids, Nonesterified | 5 | 2001 | 159 | 0.090 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 230 | 0.090 |
Why?
| | Muscle Fatigue | 1 | 2012 | 102 | 0.090 |
Why?
| | Cartilage, Articular | 1 | 2015 | 311 | 0.090 |
Why?
| | Longevity | 2 | 2024 | 165 | 0.090 |
Why?
| | Kinetics | 5 | 2003 | 1670 | 0.090 |
Why?
| | Perception | 2 | 2013 | 359 | 0.090 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1236 | 0.090 |
Why?
| | Dinoprostone | 1 | 2011 | 191 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 530 | 0.080 |
Why?
| | Athletes | 1 | 2014 | 423 | 0.080 |
Why?
| | Single-Blind Method | 3 | 2016 | 282 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 532 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 1999 | 1291 | 0.080 |
Why?
| | Parity | 1 | 2010 | 126 | 0.080 |
Why?
| | Cohort Studies | 2 | 2012 | 5742 | 0.080 |
Why?
| | Contraceptive Agents | 1 | 2010 | 66 | 0.080 |
Why?
| | Bayes Theorem | 2 | 2022 | 405 | 0.080 |
Why?
| | Androgens | 2 | 2017 | 187 | 0.080 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 810 | 0.080 |
Why?
| | Antiparkinson Agents | 2 | 2022 | 27 | 0.080 |
Why?
| | Chronic Pain | 1 | 2013 | 262 | 0.080 |
Why?
| | Depression | 1 | 2018 | 1397 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2013 | 1091 | 0.080 |
Why?
| | Efficiency | 1 | 1989 | 99 | 0.080 |
Why?
| | Advance Care Planning | 1 | 2012 | 209 | 0.080 |
Why?
| | Respiration | 4 | 2015 | 199 | 0.080 |
Why?
| | Bone Diseases, Metabolic | 2 | 2019 | 63 | 0.080 |
Why?
| | Carbon Dioxide | 2 | 2010 | 267 | 0.070 |
Why?
| | Muscle Contraction | 1 | 2011 | 424 | 0.070 |
Why?
| | Rats | 8 | 2024 | 5647 | 0.070 |
Why?
| | Mechanotransduction, Cellular | 1 | 2009 | 111 | 0.070 |
Why?
| | Calcium Citrate | 1 | 2008 | 1 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2009 | 307 | 0.070 |
Why?
| | Spectrum Analysis | 2 | 2019 | 91 | 0.070 |
Why?
| | Executive Function | 1 | 2013 | 451 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 786 | 0.070 |
Why?
| | Dietary Fats | 4 | 2013 | 304 | 0.070 |
Why?
| | Ventricular Function, Left | 3 | 2023 | 534 | 0.070 |
Why?
| | Cytokines | 1 | 2015 | 2085 | 0.070 |
Why?
| | Low Back Pain | 1 | 2008 | 108 | 0.070 |
Why?
| | Norepinephrine | 2 | 2021 | 204 | 0.070 |
Why?
| | Leg | 3 | 2002 | 236 | 0.070 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1509 | 0.060 |
Why?
| | Electric Stimulation | 1 | 2007 | 264 | 0.060 |
Why?
| | Cell Differentiation | 3 | 2021 | 1991 | 0.060 |
Why?
| | Carrier Proteins | 2 | 2005 | 771 | 0.060 |
Why?
| | Risk Reduction Behavior | 1 | 2008 | 220 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1457 | 0.060 |
Why?
| | Densitometry | 2 | 1998 | 36 | 0.060 |
Why?
| | Radioimmunoassay | 1 | 2005 | 173 | 0.060 |
Why?
| | Buttocks | 1 | 2005 | 14 | 0.060 |
Why?
| | Follicular Phase | 1 | 2005 | 39 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 219 | 0.060 |
Why?
| | Blood Coagulation Disorders | 1 | 2007 | 173 | 0.060 |
Why?
| | Cell Lineage | 2 | 2017 | 350 | 0.060 |
Why?
| | Calorimetry, Indirect | 2 | 2017 | 84 | 0.050 |
Why?
| | Nutritional Status | 2 | 2019 | 350 | 0.050 |
Why?
| | Colorado | 4 | 2019 | 4565 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2074 | 0.050 |
Why?
| | Administration, Oral | 2 | 2018 | 816 | 0.050 |
Why?
| | Plethysmography | 2 | 2022 | 106 | 0.050 |
Why?
| | Pulse Wave Analysis | 1 | 2024 | 272 | 0.050 |
Why?
| | Endometrium | 1 | 2003 | 58 | 0.050 |
Why?
| | Models, Animal | 1 | 2004 | 384 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2015 | 431 | 0.050 |
Why?
| | ADP-ribosyl Cyclase 1 | 2 | 2013 | 38 | 0.050 |
Why?
| | Liver | 3 | 2024 | 1943 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2019 | 15657 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 2 | 2013 | 269 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 106 | 0.050 |
Why?
| | Disease Progression | 1 | 2010 | 2757 | 0.050 |
Why?
| | Skinfold Thickness | 2 | 1992 | 46 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 294 | 0.050 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 57 | 0.050 |
Why?
| | Preoperative Period | 2 | 2014 | 129 | 0.050 |
Why?
| | Diphtheria Toxin | 1 | 2022 | 66 | 0.050 |
Why?
| | Food Deprivation | 2 | 2000 | 25 | 0.050 |
Why?
| | Knee | 2 | 1997 | 68 | 0.050 |
Why?
| | Osteocytes | 1 | 2001 | 28 | 0.050 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2022 | 131 | 0.050 |
Why?
| | Lipoproteins | 2 | 2000 | 168 | 0.050 |
Why?
| | Eating | 2 | 2001 | 380 | 0.050 |
Why?
| | Survival Analysis | 2 | 2015 | 1325 | 0.050 |
Why?
| | Movement | 2 | 2014 | 278 | 0.050 |
Why?
| | Postoperative Period | 2 | 2014 | 342 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2002 | 120 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 310 | 0.040 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 124 | 0.040 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 9 | 0.040 |
Why?
| | Tibia | 2 | 2019 | 178 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2005 | 594 | 0.040 |
Why?
| | Signal Transduction | 2 | 2021 | 5079 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 485 | 0.040 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 67 | 0.040 |
Why?
| | Musculoskeletal Physiological Phenomena | 1 | 2000 | 8 | 0.040 |
Why?
| | Adiponectin | 1 | 2022 | 244 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 2022 | 413 | 0.040 |
Why?
| | Kidney | 2 | 1998 | 1468 | 0.040 |
Why?
| | Child Development | 1 | 1985 | 475 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2167 | 0.040 |
Why?
| | Electric Conductivity | 1 | 2019 | 86 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 186 | 0.040 |
Why?
| | Blood Circulation | 1 | 1999 | 41 | 0.040 |
Why?
| | Orchiectomy | 1 | 2019 | 71 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 93 | 0.040 |
Why?
| | Fasting | 1 | 2001 | 281 | 0.040 |
Why?
| | Electrocardiography | 2 | 2020 | 629 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 123 | 0.040 |
Why?
| | Anthropometry | 2 | 2017 | 213 | 0.040 |
Why?
| | Muscle Development | 1 | 2000 | 111 | 0.040 |
Why?
| | Radius | 1 | 2019 | 39 | 0.040 |
Why?
| | Physician's Role | 1 | 2001 | 211 | 0.040 |
Why?
| | Collagen | 1 | 2001 | 452 | 0.040 |
Why?
| | Attitude | 1 | 2001 | 259 | 0.040 |
Why?
| | Actigraphy | 1 | 2019 | 110 | 0.040 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 41 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2020 | 233 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 584 | 0.040 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 49 | 0.040 |
Why?
| | North Carolina | 1 | 2018 | 110 | 0.040 |
Why?
| | Isometric Contraction | 2 | 2010 | 188 | 0.040 |
Why?
| | Feasibility Studies | 2 | 2015 | 956 | 0.040 |
Why?
| | Administration, Topical | 1 | 2018 | 151 | 0.040 |
Why?
| | Socioeconomic Factors | 2 | 2013 | 1289 | 0.040 |
Why?
| | Conservative Treatment | 1 | 2018 | 33 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2019 | 137 | 0.040 |
Why?
| | Mental Health | 2 | 2015 | 726 | 0.030 |
Why?
| | Ventricular Remodeling | 1 | 2000 | 266 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 145 | 0.030 |
Why?
| | Transcriptome | 1 | 2024 | 971 | 0.030 |
Why?
| | Pregnancy | 1 | 2010 | 6763 | 0.030 |
Why?
| | Hamstring Muscles | 1 | 2017 | 20 | 0.030 |
Why?
| | Goserelin | 1 | 2017 | 7 | 0.030 |
Why?
| | Nephrectomy | 1 | 1998 | 169 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 430 | 0.030 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 20 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 530 | 0.030 |
Why?
| | Blood | 2 | 1995 | 107 | 0.030 |
Why?
| | Psychometrics | 1 | 2001 | 720 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 1997 | 99 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 1989 | 3566 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 54 | 0.030 |
Why?
| | Adipogenesis | 1 | 2017 | 55 | 0.030 |
Why?
| | Cell Size | 1 | 1996 | 91 | 0.030 |
Why?
| | Fibrin | 1 | 2017 | 81 | 0.030 |
Why?
| | Joints | 1 | 1997 | 105 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 232 | 0.030 |
Why?
| | Heart | 1 | 2020 | 655 | 0.030 |
Why?
| | Accelerometry | 1 | 2017 | 103 | 0.030 |
Why?
| | Child | 3 | 2024 | 21935 | 0.030 |
Why?
| | Cell Fusion | 1 | 2015 | 51 | 0.030 |
Why?
| | Glycogen | 1 | 1996 | 55 | 0.030 |
Why?
| | Monosaccharide Transport Proteins | 1 | 1996 | 51 | 0.030 |
Why?
| | Affect | 1 | 2018 | 292 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2017 | 148 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 1998 | 275 | 0.030 |
Why?
| | Mental Status Schedule | 1 | 2015 | 33 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 21 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2847 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 180 | 0.030 |
Why?
| | Capillaries | 1 | 1996 | 108 | 0.030 |
Why?
| | Fatty Acids | 1 | 1998 | 443 | 0.030 |
Why?
| | Calibration | 1 | 1995 | 146 | 0.030 |
Why?
| | Neurophysiology | 1 | 2015 | 12 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 73 | 0.030 |
Why?
| | Databases, Bibliographic | 1 | 2015 | 32 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 332 | 0.030 |
Why?
| | Muscular Atrophy | 1 | 1995 | 86 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 669 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2001 | 560 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 827 | 0.030 |
Why?
| | Arthrometry, Articular | 1 | 2014 | 9 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2018 | 546 | 0.030 |
Why?
| | Progesterone | 1 | 2015 | 254 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2007 | 3284 | 0.030 |
Why?
| | Cholesterol Esters | 1 | 1993 | 8 | 0.030 |
Why?
| | Models, Biological | 2 | 1999 | 1783 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 39 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2015 | 266 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2013 | 49 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 19 | 0.030 |
Why?
| | Citrates | 1 | 1993 | 44 | 0.030 |
Why?
| | Epinephrine | 1 | 1993 | 139 | 0.030 |
Why?
| | Calorimetry | 1 | 2013 | 70 | 0.020 |
Why?
| | Anaerobic Threshold | 1 | 1992 | 28 | 0.020 |
Why?
| | United States | 1 | 2010 | 14841 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2014 | 177 | 0.020 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 180 | 0.020 |
Why?
| | Comorbidity | 1 | 1998 | 1622 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2013 | 67 | 0.020 |
Why?
| | Appetite | 1 | 2013 | 69 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2734 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2012 | 101 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2013 | 155 | 0.020 |
Why?
| | Upper Extremity | 1 | 2013 | 99 | 0.020 |
Why?
| | Somatomedins | 1 | 1991 | 27 | 0.020 |
Why?
| | Apolipoproteins B | 1 | 1991 | 43 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 660 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2013 | 135 | 0.020 |
Why?
| | Counseling | 1 | 2015 | 391 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 329 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2035 | 0.020 |
Why?
| | Glycoproteins | 1 | 1993 | 342 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 271 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 622 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2013 | 224 | 0.020 |
Why?
| | Viral Load | 1 | 2013 | 466 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2012 | 228 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1250 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 56 | 0.020 |
Why?
| | Hypertension | 1 | 2000 | 1295 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 898 | 0.020 |
Why?
| | Computational Biology | 1 | 2015 | 644 | 0.020 |
Why?
| | Glycogen Storage Disease Type V | 1 | 1990 | 1 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 500 | 0.020 |
Why?
| | Physical Phenomena | 1 | 2010 | 13 | 0.020 |
Why?
| | Hyperglycemia | 2 | 1991 | 347 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 347 | 0.020 |
Why?
| | Blood Vessels | 1 | 1991 | 187 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2607 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 1070 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4193 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 558 | 0.020 |
Why?
| | Macrophages | 1 | 2017 | 1547 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 352 | 0.020 |
Why?
| | Spirometry | 1 | 2010 | 281 | 0.020 |
Why?
| | Body Temperature | 1 | 2010 | 222 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1142 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1062 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 3 | 2000 | 2486 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3457 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 600 | 0.020 |
Why?
| | Iodine Radioisotopes | 2 | 1998 | 145 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2008 | 233 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4295 | 0.020 |
Why?
| | Respiratory Muscles | 1 | 1987 | 33 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 66 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 900 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 183 | 0.020 |
Why?
| | Neoplasms | 1 | 2001 | 2671 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 4030 | 0.020 |
Why?
| | Aerobiosis | 1 | 1985 | 21 | 0.010 |
Why?
| | Orthotic Devices | 1 | 1985 | 23 | 0.010 |
Why?
| | Shoes | 1 | 1985 | 18 | 0.010 |
Why?
| | DNA | 1 | 2012 | 1459 | 0.010 |
Why?
| | Body Height | 1 | 1985 | 199 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2008 | 766 | 0.010 |
Why?
| | Endometrial Hyperplasia | 1 | 2003 | 8 | 0.010 |
Why?
| | Uterine Hemorrhage | 1 | 2003 | 37 | 0.010 |
Why?
| | Inflammation | 1 | 2013 | 2837 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2004 | 309 | 0.010 |
Why?
| | Vascular Resistance | 2 | 1993 | 375 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2654 | 0.010 |
Why?
| | Infusions, Intravenous | 2 | 1991 | 413 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 2000 | 39 | 0.010 |
Why?
| | Isoflavones | 1 | 1999 | 26 | 0.010 |
Why?
| | Biopsy | 1 | 2003 | 1129 | 0.010 |
Why?
| | Hindlimb | 1 | 2000 | 128 | 0.010 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2000 | 131 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1999 | 125 | 0.010 |
Why?
| | Vibration | 1 | 1999 | 72 | 0.010 |
Why?
| | Organ Size | 1 | 2000 | 477 | 0.010 |
Why?
| | Elasticity | 1 | 1999 | 197 | 0.010 |
Why?
| | Uterus | 1 | 2000 | 215 | 0.010 |
Why?
| | Acoustic Stimulation | 1 | 1999 | 312 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1997 | 115 | 0.010 |
Why?
| | Analgesics | 1 | 1999 | 206 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 332 | 0.010 |
Why?
| | Creatinine | 1 | 1998 | 499 | 0.010 |
Why?
| | Glucose Transporter Type 4 | 1 | 1996 | 40 | 0.010 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 1993 | 20 | 0.010 |
Why?
| | Citric Acid | 1 | 1993 | 33 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1993 | 171 | 0.010 |
Why?
| | Citrate (si)-Synthase | 1 | 1992 | 60 | 0.010 |
Why?
| | Breath Tests | 1 | 1992 | 87 | 0.010 |
Why?
| | Cell Membrane | 1 | 1996 | 738 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1991 | 77 | 0.010 |
Why?
| | Hormones | 1 | 1992 | 143 | 0.010 |
Why?
| | Mitochondria, Muscle | 1 | 1992 | 116 | 0.010 |
Why?
| | Glucosephosphates | 1 | 1990 | 3 | 0.010 |
Why?
| | Glucose-6-Phosphate | 1 | 1990 | 6 | 0.010 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 1990 | 14 | 0.010 |
Why?
| | Hypercholesterolemia | 1 | 1991 | 106 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 1990 | 2 | 0.010 |
Why?
| | C-Peptide | 1 | 1991 | 163 | 0.010 |
Why?
| | Lipoproteins, HDL | 1 | 1990 | 77 | 0.000 |
Why?
| | Heart Diseases | 1 | 1993 | 346 | 0.000 |
Why?
| | Fatigue | 1 | 1991 | 329 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1990 | 560 | 0.000 |
Why?
| | Erythrocyte Volume | 1 | 1987 | 6 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1987 | 8 | 0.000 |
Why?
| | Plasma Volume | 1 | 1987 | 19 | 0.000 |
Why?
| | Oxygen | 1 | 1985 | 931 | 0.000 |
Why?
|
|
Kohrt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|